Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.47 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 11/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.44 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573034 | 1.00 | KIF11 (0.47) | KIF11NISCHSCN5AAURKATPX2 | |
| SCHEMBL41971 | 0.86 | MAPT (0.42) | KIF11NISCHMAPTEPHX2NOTUM | |
| SCHEMBL28109965 | 0.84 | GPR3 (0.42) | KIF11NISCHSCN5AAURKATPX2 | |
| SCHEMBL28046390 | 0.84 | MAPT (0.41) | KIF11NISCHMAPTEPHX2NOTUM | |
| SCHEMBL28513358 | 0.84 | MAPT (0.41) | KIF11NISCHMAPTEPHX2NOTUM | |
| SCHEMBL5542330 | 0.83 | AURKA (0.38) | KIF11NISCHSCN5AAURKATPX2 | |
| SCHEMBL27629692 | 0.83 | KIF11 (0.34) | KIF11NISCHSCN5AAURKATPX2 | |
| SCHEMBL920510 | 0.83 | EPHX2 (0.42) | KIF11NISCHSCN5AMAPTEPHX2 | |
| SCHEMBL28175586 | 0.80 | MAPT (0.42) | NISCHAURKATPX2MAPTEPHX2 | |
| SCHEMBL22344996 | 0.79 | AURKA (0.45) | KIF11NISCHSCN5AAURKATPX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017078927-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2017-05-11 | — | — | WO | claimed |
| EP-3116851-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | Salk Institute for Biological Studies (US) | 2017-01-18 | — | — | EP | claimed |
| WO-2015138969-A1 | ANALOGS OF FEXARAMINE AND METHODS OF MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2015-09-17 | — | — | WO | claimed |
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421848-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | claimed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-7718769-B2 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-7601709-B2 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2009-10-13 | — | — | US | claimed |
| WO-2007135529-A2 | AZABENZIMIDAZOLYL COMPOUNDS AS MGLUR2 POTENTIATORS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | claimed |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-11-24 | — | — | US | claimed |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | GRUENENTHAL GMBH (DE) | 2005-08-25 | — | — | US | claimed |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | claimed |
| EP-1546089-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TransTech Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | claimed |
| WO-2005014533-A2 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | claimed |
| WO-2004113365-A2 | HEPATITIS C SERINE PROTEASE TRI-PEPTIDE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | WO | claimed |
| WO-2004081005-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TRANSTECH PHARMA, LLC | 2004-06-10 | — | — | US | claimed |
| WO-2004014844-A2 | ARYL AND HETEROARYL COMPOUNDS AND METHODS TO MODULATE COAGULATION | TRANSTECH PHARMA, INC. (US) | 2004-02-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110832-A1 | management, treatment and/or control of diseases caused in intrinsic clotting pathway utilizing factor IX such as stroke, myocardial infarction, aneurysm surgery, and deep vein thrombosis associated with surgical procedures etc | TFPI, F9, TFPI2 | KIF11 3454/4885NISCH 963/4885SCN5A 522/4885 |
| US-20050261200-A1 | Tri-peptide hepatitis C serine protease inhibitors | PRSS1, VIP, HPN | KIF11 4618/4885NISCH 1324/4885SCN5A 2032/4885 |
| US-20050187260-A1 | 2-Pyrrolidin-2-yl-[1,3,4]-oxadiazole compounds and their use as anti-depressants | OPRD1, OPRK1, GRIN2C | KIF11 2227/4885NISCH 2337/4885SCN5A 488/4885 |
| US-20050153877-A1 | Macrocyclic hepatitis C serine protease inhibitors | PRSS1, SPINT2, TMPRSS4 | KIF11 4517/4885NISCH 583/4885SCN5A 1800/4885 |
| US-20050059705-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F3, F2 | KIF11 4478/4885NISCH 227/4885SCN5A 1058/4885 |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | KIF11 4060/4885NISCH 404/4885SCN5A 1495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.